Jubilant Life Sciences has announced that its wholly-owned subsidiary, Jubilant Pharma, has received final USFDA approval for its ANDA Niacin ER Tablets. The approval in three strengths i.e. 500 mg, 750 mg, and 1,000 mg.  Niacin ER is a generic version of Niaspan tablet which is manufactured and marketed by AbbVie.

Niacin ER is indicated to reduce the risk of recurrent nonfatal myocardial infarction in patients with a history of myocardial infarction and hyperlipidemia. The company as on March 31, 2018, had 94 ANDAs for oral solids filed in the US. Of this, 59 had been approved. It also has 12 sterile (injectables and ophthalmics) filings, of which 10 had been approved. Niacin currently has 5-6 players and had a US market of ~USD 320 million by end of 2018. – India Infoline

10 Diagnostic Imaging Trends for 2018



Digital version